Literature DB >> 24121212

Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients.

J A Hol1, T F W Wolfs1, M B Bierings1, C A Lindemans1, A B J Versluys1, A Wildt de1, C E Gerhardt1, J J Boelens1.   

Abstract

This study was aimed at finding predictors of invasive fungal infection (IFI) after pediatric allogeneic hematopoietic SCT (HSCT). All children who received allogeneic HSCT in the Wilhelmina Children's Hospital Utrecht between 2004 and 2012 were included. HSCT data were prospectively collected. Patients were retrospectively classified into high- or low-risk groups for developing IFI using criteria based on available literature. Predictors for the occurrence of IFI were analyzed using Cox regression models. We used logistic regression models to analyze the association between other HSCT-related complications and IFI. Secondary outcomes were overall survival and treatment-related mortality (TRM). Two-hundred nine patients were included in the analysis; median age was 6.6 years. The cumulative incidence of IFI was 12%. In patients classified as 'low risk' (n=75), only 5.3% developed IFI (odds ratio (OR): 0.325; P=0.047). In multivariate analysis, a predictor for the occurrence of IFI was an a priori determined HSCT TRM risk >20% (based on EBMT-risk score). Post-HSCT, the administration of high-dose steroids was associated with IFI (OR: 4.458; P=0.010). Patients who developed IFI showed an increased risk of TRM (OR: 3.773; P=0.004). These results confirm that risk group stratification should guide intensity of monitoring for IFI and use of antifungal prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24121212     DOI: 10.1038/bmt.2013.136

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  23 in total

Review 1.  Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients.

Authors:  Penelope D Barnes; Kieren A Marr
Journal:  Br J Haematol       Date:  2007-11       Impact factor: 6.998

2.  Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.

Authors:  L Hovi; U M Saarinen-Pihkala; K Vettenranta; H Saxen
Journal:  Bone Marrow Transplant       Date:  2000-11       Impact factor: 5.483

3.  Infections diagnosed in the first year after pediatric stem cell transplantation.

Authors:  Daniel Kelly Benjamin; William C Miller; Sherry Bayliff; Lisa Martel; Kenneth A Alexander; Paul Langlie Martin
Journal:  Pediatr Infect Dis J       Date:  2002-03       Impact factor: 2.129

Review 4.  The EBMT risk score.

Authors:  A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2011-06-06       Impact factor: 5.483

Review 5.  Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.

Authors:  Christopher C Blyth; Katherine Hale; Pamela Palasanthiran; Tracey O'Brien; Michael H Bennett
Journal:  Cochrane Database Syst Rev       Date:  2010-02-17

6.  Invasive mycoses in children receiving hemopoietic SCT.

Authors:  E Castagnola; M Faraci; C Moroni; R Bandettini; C Granata; S Caruso; F Bagnasco; I Caviglia; M Malgorzata; E Furfaro; A R Natalizia; V de Fazio; G Morreale; E Lanino; R Haupt; G Dini; C Viscoli
Journal:  Bone Marrow Transplant       Date:  2008-06       Impact factor: 5.483

7.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients.

Authors:  M Mikulska; A M Raiola; B Bruno; E Furfaro; M T Van Lint; S Bregante; A Ibatici; V Del Bono; A Bacigalupo; C Viscoli
Journal:  Bone Marrow Transplant       Date:  2009-03-23       Impact factor: 5.483

9.  What are fungal infections?

Authors:  Ben E de Pauw
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-01-14       Impact factor: 2.576

10.  Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism.

Authors:  Eveline Snelders; Henrich A L van der Lee; Judith Kuijpers; Anthonius J M M Rijs; János Varga; Robert A Samson; Emilia Mellado; A Rogier T Donders; Willem J G Melchers; Paul E Verweij
Journal:  PLoS Med       Date:  2008-11-11       Impact factor: 11.069

View more
  11 in total

1.  Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.

Authors:  P Montesinos; R Rodríguez-Veiga; B Boluda; D Martínez-Cuadrón; I Cano; A Lancharro; J Sanz; M J Arilla; F López-Chuliá; I Navarro; I Lorenzo; M Salavert; J Pemán; P Calvillo; J Martínez; N Carpio; I Jarque; G F Sanz; M A Sanz
Journal:  Bone Marrow Transplant       Date:  2015-08-17       Impact factor: 5.483

2.  Possible roads to improve hemophagocytic lymphohistiocytosis outcome.

Authors:  Pietro Merli; Michael B Jordan; Franco Locatelli
Journal:  Blood Adv       Date:  2020-12-22

Review 3.  Extended Dosing Regimens for Fungal Prophylaxis.

Authors:  Thomas Lehrnbecher; Konrad Bochennek; Thomas Klingebiel; Silke Gastine; Georg Hempel; Andreas H Groll
Journal:  Clin Microbiol Rev       Date:  2019-05-15       Impact factor: 26.132

Review 4.  Fungal infections in children with haematologic malignancies and stem cell transplant recipients.

Authors:  William R Otto; Abby M Green
Journal:  Br J Haematol       Date:  2020-03-11       Impact factor: 6.998

5.  A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.

Authors:  Christopher C Dvorak; Brian T Fisher; Adam J Esbenshade; Michael L Nieder; Sarah Alexander; William J Steinbach; Ha Dang; Doojduen Villaluna; Lu Chen; Micah Skeens; Theoklis E Zaoutis; Lillian Sung
Journal:  J Pediatric Infect Dis Soc       Date:  2021-04-30       Impact factor: 3.164

6.  A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.

Authors:  Antonio C Arrieta; Lillian Sung; John S Bradley; C Michel Zwaan; Davis Gates; Hetty Waskin; Patricia Carmelitano; Andreas H Groll; Thomas Lehrnbecher; Eric Mangin; Amita Joshi; Nicholas A Kartsonis; Thomas J Walsh; Amanda Paschke
Journal:  PLoS One       Date:  2019-03-26       Impact factor: 3.240

7.  Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia-A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP.

Authors:  Herbert Pichler; Anita Lawitschka; Evgenia Glogova; Andre M Willasch; Irene von Luettichau; Thomas Lehrnbecher; Susanne Matthes-Martin; Peter Lang; Peter Bader; Karl W Sykora; Johanna Schrum; Bernhard Kremens; Karoline Ehlert; Michael H Albert; Michaela Kuhlen; Roland Meisel; Tayfun Guengoer; Brigitte Strahm; Bernd Gruhn; Ansgar Schulz; Wilhelm Woessmann; Ulrike Poetschger; Christina Peters
Journal:  Am J Hematol       Date:  2019-05-29       Impact factor: 10.047

8.  Pediatric Antifungal Prescribing Patterns Identify Significant Opportunities to Rationalize Antifungal Use in Children.

Authors:  Laura Ferreras-Antolín; Adam Irwin; Ayad Atra; Faye Chapelle; Simon B Drysdale; Marieke Emonts; Paddy McMaster; Stephane Paulus; Sanjay Patel; Menie Rompola; Stefania Vergnano; Elizabeth Whittaker; Adilia Warris
Journal:  Pediatr Infect Dis J       Date:  2022-03-01       Impact factor: 2.129

9.  Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.

Authors:  Agnieszka Sobkowiak-Sobierajska; Caroline Lindemans; Tomas Sykora; Jacek Wachowiak; Jean-Hugues Dalle; Halvard Bonig; Andrew Gennery; Anita Lawitschka
Journal:  Front Pediatr       Date:  2022-02-18       Impact factor: 3.418

Review 10.  Diagnostic Approaches for Invasive Aspergillosis-Specific Considerations in the Pediatric Population.

Authors:  Thomas Lehrnbecher; Angela Hassler; Andreas H Groll; Konrad Bochennek
Journal:  Front Microbiol       Date:  2018-03-26       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.